Table 1.
Proteins | Marginal inclusion probability | Model-averaged causal effect | Empirical P-value | FDR P-value |
---|---|---|---|---|
GPC1 | 0.993 | − 0.349 | 0.001 | 0.013 |
NAMPT | 0.433 | 0.113 | 0.005 | 0.022 |
NCF2 | 0.324 | 0.066 | 0.005 | 0.022 |
PDE4D | 0.309 | 0.079 | 0.063 | 0.174 |
FSTL1 | 0.165 | − 0.048 | 0.122 | 0.243 |
CBR1 | 0.157 | 0.049 | 0.131 | 0.243 |
TIE1 | 0.136 | 0.016 | 0.067 | 0.174 |
PTPN4 | 0.041 | − 0.008 | 0.988 | 1.000 |
PAFAH1B2 | 0.031 | − 0.005 | 0.997 | 1.000 |
SOCS3 | 0.028 | − 0.003 | 0.948 | 1.000 |
Marginal inclusion probability for the protein, representing the probability of that protein being a causal determinant of MM risk. Model-averaged causal effect represents the average causal effect across models including that protein. Empirical P-values are computed using 1000 permutations and adjusted for multiple testing using false-discovery rate (FDR) procedure
CBR1 carbonyl reductase 1, FSTL1 follistatin-related protein 1, FDR false discovery rate, GPC1 glypican 1, NAMPT nicotinamide phosphoribosyl transferase, NCF2 neutrophil cytosol factor 2, PAFAH1B2 platelet-activating factor acetyl hydrolase IB subunit beta, PDE4D cAMP-specific 3',5'-cyclic phosphodiesterase 4D, PTPN4 protein tyrosine phosphatase non-receptor type 4, SOCS3 suppressor of cytokine signaling 3, TIE1 tyrosine kinase with immunoglobulin-like and EGF-like domains 1, SNP single nucleotide polymorphism